Patents by Inventor Soren Ebdrup

Soren Ebdrup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9056814
    Abstract: The present invention relates to the crystalline, polymorphic Form C of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: June 16, 2015
    Assignee: LEO PHARMA A/S
    Inventors: Soren Ebdrup, Kim Troensegaard Nielsen, Tanja Maria Greve
  • Patent number: 8946474
    Abstract: The present invention relates to the crystalline, polymorphic Form X of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use. The invention also relates to the preparation of Form X by crystallization from a saturated solution of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid in a C1-C6 alkyl alcohol, or alternatively by precipitation from a neutralized saponification reaction mixture following the alkaline hydrolysis of a C1-C6 alkyl ester of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: February 3, 2015
    Assignee: LEO Pharma A/S
    Inventors: Søren Ebdrup, Kim Troensegaard Nielsen, Tanja Maria Greve
  • Patent number: 8927549
    Abstract: Embodiments of the present invention provide adamantyl benzamide derivatives and pharmaceutical compositions comprising adamantyl benzamide derivatives. Methods of use of such compounds and compositions to modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) in a subject are also provided.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: January 6, 2015
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Dharma Rao Polisetti, Suparna Gupta, Soren Ebdrup
  • Patent number: 8907096
    Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 9, 2014
    Assignee: High Point Pharmaceuticals, LLC
    Inventor: Soren Ebdrup
  • Publication number: 20140315905
    Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventor: Soren Ebdrup
  • Patent number: 8809540
    Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 19, 2014
    Assignee: High Point Pharmaceuticals, LLC
    Inventor: Soren Ebdrup
  • Publication number: 20130231341
    Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
    Type: Application
    Filed: January 11, 2013
    Publication date: September 5, 2013
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventor: Soren Ebdrup
  • Patent number: 8470964
    Abstract: The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,11 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity or survival of cells. Further, the present invention relates to the use of the compounds for production of a medicament for treatment of conditions and diseases, in which NCAM or FGFR play a prominent role.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: June 25, 2013
    Assignee: Enkam Pharmaceuticals A/S
    Inventors: Vladimir Berezin, Elisabeth Bock, Soren Ebdrup, Boris Klementiev
  • Publication number: 20130143846
    Abstract: The present invention relates to the crystalline, polymorphic Form X of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use. The invention also relates to the preparation of Form X by crystallization from a saturated solution of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid in a C1-C6 alkyl alcohol, or alternatively by precipitation from a neutralized saponification reaction mixture following the alkaline hydrolysis of a C1-C6 alkyl ester of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid.
    Type: Application
    Filed: June 24, 2011
    Publication date: June 6, 2013
    Applicant: LEO PHARMA A/S
    Inventors: Søren Ebdrup, Kim Troensegaard Nielsen, Tanja Maria Greve
  • Publication number: 20130131023
    Abstract: The present invention relates to the crystalline, polymorphic Form C of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 23, 2013
    Applicant: LEO PHARMA A/S
    Inventors: Soren Ebdrup, Kim Troensegaard Nielsen, Tanja Maria Greve
  • Patent number: 8426473
    Abstract: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-? and should be useful for treating conditions mediated by the same.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: April 23, 2013
    Assignee: High Point Pharnaceuticals, LLC
    Inventor: Soren Ebdrup
  • Patent number: 8383668
    Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSDI and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: February 26, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Soren Ebdrup, Henrik Sune Andersen
  • Patent number: 8383820
    Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: February 26, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventor: Soren Ebdrup
  • Patent number: 8383683
    Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydro-genase type 1 (11?HSD1) and the use of these compounds as pharmaceutical composi-tions, are described. Also a novel class of substituted amides, their use in therapy, phar-maceutical compositions comprising the compounds, as well as their use in the manufac-ture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active gluco-corticoid is desirable.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: February 26, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Soren Ebdrup, Henrik Sune Andersen
  • Patent number: 8334305
    Abstract: Novel substituted amide inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: December 18, 2012
    Assignee: High Point Pharmaceuticals, LLC
    Inventor: Soren Ebdrup
  • Publication number: 20120232080
    Abstract: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-? and should be useful for treating conditions mediated by the same.
    Type: Application
    Filed: May 8, 2012
    Publication date: September 13, 2012
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventor: Soren Ebdrup
  • Patent number: 8217086
    Abstract: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-? and should be useful for treating conditions mediated by the same.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: July 10, 2012
    Assignee: High Point Pharmaceuticals, LLC
    Inventor: Soren Ebdrup
  • Publication number: 20120010194
    Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSDI and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 12, 2012
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: Soren Ebdrup, Henrik Sune Andersen
  • Publication number: 20120004209
    Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11?-hydroxy-steroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.
    Type: Application
    Filed: September 19, 2011
    Publication date: January 5, 2012
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: Soren Ebdrup, Henrik Sune Andersen
  • Publication number: 20110312949
    Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.
    Type: Application
    Filed: August 30, 2011
    Publication date: December 22, 2011
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: John Paul Kilburn, Henrik Sune Andersen, Gita Camilla Tejlgaard Kampen, Soren Ebdrup